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Griscelli syndrome type 2 (GS-2) is an inborn error of immunity characterized by partial
albinism and episodes of hemophagocytic lymphohistiocytosis (HLH). It is caused by
RAB27A mutations that encode RAB27A, a member of the Rab GTPase family. RAB27A
is expressed in many tissues and regulates vesicular transport and organelle dynamics.
Occasionally, GS-2 patients with RAB27Amutation display normal pigmentation. The study
of such variants provides the opportunity to map distinct binding sites for tissue-specific
effectors on RAB27A. Here we present a new case of GS-2 without albinism (GS-2 sine
albinism) caused by a novel missense mutation (Val143Ala) in the RAB27A and characterize
its functional cellular consequences. Using pertinent animal cell lines, the Val143Ala
mutation impairs both the RAB27A–SLP2-A interaction and RAB27A–MUNC13-4
interaction, but it does not affect the RAB27A–melanophilin (MLPH)/SLAC2-A interaction
that is crucial for skin and hair pigmentation. We conclude that disruption of the RAB27A–
MUNC13-4 interaction in cytotoxic lymphocytes leads to the HLH predisposition of the GS-
2 patient with the Val143Ala mutation. Finally, we include a review of GS-2 sine albinism
cases reported in the literature, summarizing their genetic and clinical characteristics.
Keywords: Griscelli syndrome type 2 sine albinism, whole-exome sequencing, hemophagocytic lymphohistiocytosis,
RAB27A, MLPH/SLAC2-A, MUNC13-4, inborn error of immunityINTRODUCTION
Griscelli syndrome type 2 (GS-2; MIM#607624) is an inborn error of immunity (IEI) characterized
by partial albinism and the occurrence of acute phases of hemophagocytic lymphohistiocytosis
(HLH) (1, 2). RAB27A (MIM *603868) gene mutations are responsible for GS-2. RAB27A is a
member of the small GTPase family, which is involved in organelle dynamics and intracellularorg December 2020 | Volume 11 | Article 6129771
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specific effectors and associate with cellular membranes.
RAB27A is highly expressed in melanocytes and a variety of
secretory cells, including lymphocytes (5). In mature mouse
melanocytes, RAB27A effector/melanophilin (MLPH, also known
as SLAC2-A) forms a bridge between RAB27A on mature
melanosomes and an actin-based motor myosin Va (MYO5A)
andpromotes subsequent actin-basedmelanosome transport (6, 7).
Mutations in the MYO5A (MIM*160777) encoding MYO5A and
MLPH (MIM*606526) encoding MLPH/SLAC2-A cause other
types of Griscelli syndrome GS-1 (MIM#214450) and GS-3
(MIM#609227), respectively (8, 9). Unlike GS-2 patients,
however, GS-1 patients reveal primary neurological problems,
and GS-3 patients only exhibit pigmentary dilution.
In cytotoxic T lymphocytes (CTLs), RAB27A controls secretion
of cytolytic granules by binding the priming factor MUNC13-4 (2,
10, 11). Mutations in either RAB27A or MUNC13-4 inhibit
secretion of granules once they have reached the immunologic
synapse. However, little is known about the precise sites of
interaction between RAB27A and MUNC13-4 in lymphocytes.
Recently, a subpopulation of patients with GS-2 has been
reported to present normal pigmentation despite abnormal CTL
exocytosis (12–15) (Table 1). The study ofRAB27Amutations that
specifically disrupt the interactionofRAB27AwithMUNC13-4 but
not MLPH provides the opportunity to map distinct binding sites
for MUNC13-4 and MLPH on RAB27A. Here we present a new
case of GS-2 without albinism caused by a novelmissensemutation
(Val143Ala) in the RAB27A and characterize its functional cellular
consequences. We also show and discuss genetic and clinical
findings of other patients with GS-2 sine albinism who reported
in the literature.MATERIALS AND METHODS
Materials
Horseradish peroxidase (HRP)-conjugated anti-FLAG tag mouse
monoclonal (M2) antibody, and anti-FLAG tag antibody-conjugated
agarose beads were obtained from Sigma-Aldrich (St. Louis, MO,
USA).HRP-conjugated anti-T7 tagmousemonoclonal antibody and
anti-T7 tag antibody-conjugated agarose beads were from
Novagen™, Merck KGaA (Darmstadt, Germany). Anti-GFP rabbit
polyclonal antibody and anti-b-actin mouse monoclonal antibody
(C043) were also obtained from MBL (Nagoya, Japan) and Applied
Biological Materials (Richmond, BC, Canada), respectively.
RAB27A Mutation Analysis
Blood and hair samples were obtained with informed consent
according to the Institutional Review Boards’ guidelines of the
Children’s Medical Center. Genomic DNA was obtained from
whole blood by the conventional salting-out method. Whole
exome sequencing was performed on a patient sample, as
previously described (16). PCR was carried out using primers
specific for coding exon 6 of the RAB27A gene, as described
previously (17). PCR products were directly sequenced using
internal primers with an automated ABI PRISM 310 genetic
analyzer (PE Applied Biosystems, Norwalk, CT, USA).Frontiers in Immunology | www.frontiersin.org 2T Cell Culture
Cytotoxic T cell culture (CTL) were prepared by stimulating
peripheral blood mononuclear cells (PBMCs) with PHA (1.25
mg/ml) and ∼100 U/ml human IL-2 (produced from a
transfected cell line) in the presence of irradiated (30 Gy for
5 min) allogeneic PBMCs as feeder cells. RPMI (Gibco,
ThermoFisher, UK) with 5% human serum (Sigma-Aldrich,
USA) and ∼100 U/ml human IL-2 was used as culture
medium. Every 14 to 18 days, T cells were re-stimulated as above.
Western Blotting of RAB27A
From Patient Cells
T cell cultures were washed in ice-cold sterile PBS and lysed at
2 × 107/ml in lysis buffer [50 mM Tris–HCl (pH7.4), 150 mM
NaCl, 1% Triton X-100, 1% NP-40, 2 mM EDTA, and 1x Halt™
protease inhibitors (Thermo Fisher)] for 30 min on ice before cell
debris was pelleted by centrifugation at 13,000 for 25 min at 4°C.
22.5 µl cell lysate was mixed with 7.5µl 4x NuPAGE™ LDS
reducing sample buffer [Tris base (141 mM), Tris HCl (106 mM),
LDS (2%), EDTA (0.51 mM), and 50mMDTT] and heated at 95°
C for 5 min before separation on a 4–12% NuPAGE™ Bis-Tris
gel in MES running buffer [MES (50 mM), Tris base (50 mM),
sodium dodecyl sulfate (SDS) (0.1%), EDTA (1 mM), pH 7.3 (all
Thermo Fisher)]. Precision Plus Protein Kaleidoscope Prestained
Protein Standards (Bio-Rad, Hercules, CA, USA) were also run.
Proteins were transferred to nitrocellulose membranes [Trans-
Blot® Turbo™ Mini Nitrocellulose Transfer Packs (Bio-Rad)
using the mixed molecular weight program of a semi-dry Trans-
Blot Turbo Transfer System (Bio-Rad)]. Membranes were
blocked in TBS, 5% non-fat dried milk, and 0.05% Tween-20
(Sigma-Aldrich). Membranes were incubated with primary
antibodies (rabbit anti-RAB27A (see ref.12) at 1:1,000 in
blocking buffer at 4°C overnight or 1:1,000 rabbit anti-calnexin
(C4731, Sigma-Aldrich) for 1 h at room temperature.
Membranes were washed 4× for 5 min in TBS, 0.05% Tween,
and incubated with 1:10,000 goat anti-rabbit (H+L) HRP labeled
secondary antibodies (Thermo Fisher) in blocking buffer for
45 min at room temperature. Membranes were washed as before,
developed using ECL Prime Western Blotting solution
(Amersham), and imaged using a Bio-Rad ChemiDoc.
Degranulation Assay
Degranulation of cultured T cells was analyzed at day10 after re-
stimulation, and T cells were starved overnight without IL-2 (18).
T cells were stimulated with L1210 cells alone or together with
1 µg/ml anti-CD3e (UCHT1, BD Biosciences, UK). Anti-CD107a
phycoerythrin, clone H4A3 (eBioscience, UK) was added for the
3-h stimulation time and was again used in combination with
anti-CD8 allophycocyanin, clone: MEM-31 (Abcam, UK) for
surface staining. Cells were analyzed with flow cytometry
(Attune NxT, Thermo Fisher, UK) and FlowJo software.
Cytotoxic T Lymphocytes Killing Assay
This was as described in (19). In brief, cultured CTLs were added
to the P815-NucLight Red-expressing target cells in the presence
or absence of 1 mg/ml anti-CD3 antibody (clone UCHT1,
catalogue 555330, BD Biosciences—Pharmingen), at a CTL-to-December 2020 | Volume 11 | Article 612977
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I 1 2.7 M c.428T>C Val143Ala Homo Disrupted Nl
II 2 0.5 M c.422-424delGAG Arg141—Val142delinsIle Homo Disrupted Nl
3 0.5 m M c.422-424delGAG Arg141—Val142delinsIle Homo Disrupted Nl
4 10.7 F c.422-424delGAG Arg141—Val142delinsIle Homo Disrupted Nl






























VI 8 9 F c.244C>T Arg82Cys Homo Disrupted Nl
9 8 M c.244C>T Arg82Cys Homo Disrupted Nl
10 5 M c.244C>T Arg82Cys Homo Disrupted Nl
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ATG, anti-thymocyte globulin; DEX, dexamethasone; CNS, central nervous system; GPOH-HD, German Society of Pediatri





Ohishi et al. GS-2 Sine Albinismtarget ratio of 10:1. The killing was measured by the reduction of
red fluorescence intensity, indicating target cell death. The assay
was measured every 30 min for 4 h using the IncuCyte S3 Live-
Cell Analysis System (Essen Bioscience).
Immunofluorescence Using Artificial
Immunological Synapse
Multiwell microscopy slides were cleaned with 70% ethanol for
15 min at room temperature and were coated with 0.01% poly-L-
lysine (Millipore Sigma, UK) for 15 min, washed with PBS, and
coated with 10 mg/ml hamster humanized anti-CD3 antibody
(ChAgly, a gift from Herman Waldmann). Cultured T cells were
washed and added in FCS-free IMDM and were allowed to adhere
for 12 min. Cells were fixed for 15 min in 4% paraformaldehyde
(PFA) (15710-S, Electron Microscopy Systems, USA),
permeabilized in 0.1% Triton X-100, and blocked in 2% BSA in
PBS (40min). Sampleswere labeled for 1 hwith primary antibodies
[pericentrin (Abcam, UK)] and LAMP1 (H4A3, hybridoma
supernatant) and phalloidin followed by fluorophore-conjugated
secondary antibodies (donkey anti-mouse 488 and goat anti-rabbit
647, Invitrogen, UK) (1 h at RT) together with phalloidin 568
(Invitrogen, UK).Nuclei were stained for 5min at RTwithHoechst
33342 (H3570, Thermo Fisher, UK), and samples weremounted in
ProLong Diamond Antifade Reagent (P36961, Thermo Fisher,
UK). Images were taken with an IX81 Olympus microscope
equipped with an Andor Revolution system fitted with a CSU-X1
spinning-disk unit (Yokogawa, UK).
Plasmid Construction and Site-Directed
Mutagenesis
Mutant human RAB27A expression plasmids carrying a Val-to-
Ala mutation at amino acid position 143 were produced by
inverse PCR techniques essentially as described previously (20)
using pEGFP-C1-Rab27A as a template (21) and the following
oligonucleotides with a substituted nucleotide (in bold): 5’-
GGAGGACCAGAGAGTAGCGAAAGAGGAGGAAGCCA-3’
(sense) and 5’-GCTTCCTCCTCTTTCGCTACTCTCTGGT
CCTCC-3’ (antisense). The RAB27A cDNA inserts were
excised from the vector with appropriate restriction enzymes
and subcloned into the pEF-FLAG tag mammalian expression
vector (22) and pMRX-IRES-EGFP tag retrovirus vector (23) as
described previously. Other expression plasmids, including pEF-
T7-MUNC13-4, pEF-T7-SLP2-A, pEF-T7-MLPH/SLAC2-A,
were prepared as described previously (24, 25).
Cell Cultures, Transfections, and
Stable Expression of RAB27A
The black mouse-derived immortal melanocyte cell line melan-a
and ashenmouse-derived immortal melanocyte cell linemelan-ash
were obtained from theWellcome Trust Functional Genomics Cell
Bank and cultured as describedpreviously (26–28).COS-7 cells and
Plat-E cells [a kind gift from Toshio Kitamura (The University of
Tokyo, Tokyo, Japan)] were maintained at 37°C under 5% CO2 in
DMEM (FUJIFILM Wako Pure Chemical, Osaka, Japan)
containing 10% fetal bovine serum and antibiotics. Retrovirus
production and infection were performed, as described previouslyFrontiers in Immunology | www.frontiersin.org 4(29). Stable melan-ash cell lines were obtained by blasticidin
selection (10 µg/ml for 5–7 days).
Immunofluorescence Analysis and
Melanosome Distribution Assay
Two immortal mouse melanocyte cell lines were cultured on
coverslips and fixed with 4% PFA for 10 min. The coverslips were
incubated for 1 h with DAPI. The samples were mounted using
ProLong Diamond Antifade Mountant (Thermo Fisher
Scientific, Waltham, MA). Infected cells were identified by
EGFP fluorescence, and their fluorescence images, together
with the corresponding bright-field images, were captured at
random with an FV1000D confocal fluorescence microscope and
Fluoview software (Olympus, Tokyo, Japan). Melanosome
distribution was assessed by examination of images of infected
melan-a/ash cells (more than 25 cells/dish, three independent
dishes for each transfection). Cells in which more than 50% of
the melanosomes were present around the nucleus were judged
to be aggregated as described previously (28).
Co-Immunoprecipitation Assay in
COS-7 Cells
COS-7 cells were co-transfected for 24 h with pEF-FLAG-RAB27A
(wild-typeor aVal143Alamutant) andpEF-T7-MUNC13-4, pEF-T7-
SLP2-A, or pEF-T7-MLPH/SLAC2-A by using Lipofectamine 2000
(Invitrogen, ThermoFisher Scientific). The transfected cells were lysed
witha lysisbuffer [50mMHEPES-KOH,pH7.2, 150mMNaCl, 1mM
MgCl2, and1%TritonX-100 supplementedwith completeEDTA-free
protease inhibitormixture (Roche,Basel, Switzerland)].The cell lysates
were incubated for 1 h at 4°Cwith anti-FLAGor anti-T7 tag antibody-
conjugated agarose beads. The beads were washed three times with a
washing buffer (50 mMHEPES-KOH, pH7.2, 150 mM NaCl, 1 mM
MgCl2, and 0.1%TritonX-100), and proteins bound to the beadswere
analyzed by 10% SDS-polyacrylamide gel electrophoresis (PAGE)
followed by immunoblotting with HRP-conjugated anti-FLAG and
anti-T7 tag antibodies. Immunoreactive bands were visualized by
enhanced chemiluminescence.
Statistical Analysis
Statistical tests were performed using Tukey’s test, and p values
<0.05 were considered statistically significant.RESULTS
Clinical Phenotype
The patient was a boy of Iranian origin and was born to
consanguineous parents. Informed consent was obtained from
the parents. He had no albinism, and his hair shafts showed fairly
normal pigmentation (Figures 1A–C). Laboratory data revealed a
white blood cell count of 360 cells/µL, an absolute neutrophil count
of 10 cells/µl, hemoglobin of 7.7 g/dl, and platelets of 23,000 cells/µl.
Serum chemistry revealed triglyceride of 267mg/dl (normal <160),
ferritin of 23,840 ng/ml (normal<500), and fibrinogen of 127mg/dl
(normal >150). The bone marrow exam demonstrated mild
dyserythropoiesis without any hemophagocytic changes. Epstein-December 2020 | Volume 11 | Article 612977
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patient fulfilled five HLH criteria, and secondary causes were
excluded, so he was started on an HLH-94 protocol and referred
to receive an allogenic hematopoietic stem cell transplantation. The
disease was fairly well controlled when he presented at 53 months
with left-sided Bell’s palsy. Brain MRI indicated facial nerve
demyelinating disease. The cerebrospinal fluid (CSF) analysis was
unremarkable. Methylprednisolone (30 mg/kg/day for three
consecutive days) and a dose of anti-thymocyte globulin (5 mg/
kg/day for three days) resulted in resolution of symptoms. Eight
months later, he presented with seizure and drowsiness. CSF
analysis showed lymphocytic pleocytosis and increased protein
levels. Intrathecal methotrexate/hydrocortisone was started.
However, the neurologic disease progressed over the next
months, and he developed liver failure and severe cytopenias,
leading to his death one month later.
Identification of RAB27A Mutation
Whole exome sequencing revealed a homozygousmissense c.428T>C
(Val143Ala) variant in exon 6 of RAB27A (NM_183236). No
important mutations in other genes relevant to HLH were detected,
including UNC13D, STX11, STXBP2, LYST, PRF1, SH2D1A, XIAP,
ITK,CD27,AP3B1,NLRC4, andMAGT1. Similarly, knownIEI-related
genes lacked any rare deleterious mutations. Sanger sequencing
confirmed the homozygous RAB27Amutation in the patient, while a
heterozygous mutation was found in parents and homozygous wild
type in the healthy sister (Figures 1D,E). This is a novelmutationwith
no allele reported in public databases such as gnomAD. Based on the
PolyPhen-2 amino acid change predictor, this mutation is likely
deleterious. The combined annotation dependent depletion (CADD)
score of this mutation is 25.7; higher than the mutation significance
cutoff (MSC) of 4, pertinent to RAB27A (using HGMD with 99%
confidence interval) (30).Frontiers in Immunology | www.frontiersin.org 5Degranulation and Immune Synapse
Formation Assays
In line with other homozygous mutations in the RAB27A, the
patient’s CTLs showed impaired degranulation. In contrast, the
mother’s CTLs with the heterozygous mutation showed slightly
reduced to normal degranulation compared to healthy control
(Figure 2A). Degranulation was performed in 3 independent
experiments (Figure 2B). Furthermore, we analyzed the transport
to the immunological synapse (IS) of the lytic granules by
generating an artificial synapse on microscopy slides using glass
bound anti-CD3. As an indication for synapse formation, we
stained for actin using phalloidin. At the synapse, actin is cleared,
the microtubule-organization center or centrosome (stained by
pericentrin) moves to the synapse, and the lytic granules are
transported along the microtubules to the immunological
synapse. In line with other reports of lytic granule polarization
(11, 31), the transport to the immunological synapse was normal
(Figure 2C). This is highlighted by the 90° side view of the cell,
demonstrating the localization of the lytic granules close to the
centrosome and the immunological synapse and not far back in the
cell body. However, the release of the lytic granules was impaired,
and the patient’sCTLs showed the reducedkillingof targets (Figure
2D). Despite the functional impairment, the mutated protein of
RAB27A was expressed stably in the CTLs of the patient (Figure
2E), pointing to an impaired binding activity to MUNC13-4.
Subcellular Localization and Function
of RAB27A(Val143Ala) in Cultured
Mouse Melanocytes
Toevaluate the effect of theVal143Alamutationon themelanosomal
localization of RAB27A, an EGFP (enhanced green fluorescence
protein)-tagged RAB27A (Val143Ala) mutant was stably expressedA B D
E
C
FIGURE 1 | Clinical and genetic findings of the patient (A). Normal complexion with left-sided Bell’s palsy (B). Fairly normal hair pigmentation of the patient
(Val143Ala) determined by light microscopy compared to (C) abnormal clumps of melanin characteristic of GS-2 (Lys22Arg) (D, E). Pedigree of the family showing
the familial segregation of RAB27A mutation and chromatograms pertinent to each family member.December 2020 | Volume 11 | Article 612977
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retroviral infection (Figure 3). While wild-type EGFP-RAB27A
showed a clear punctate localization on melanosomes (Figure 3,
middle panels), EGFP-RAB27A (Val143Ala) was only weakly
associated with melanosomes (Figure 3, lower panels) and some
portions of the mutant protein seemed to localize in the cytosol
similar to EGFP alone (Figure 3, top panels). As EGFP-RAB27A
(Val143Ala) had no effect on the distribution of melanosomes, in
contrast to EGFP-tagged mouse RAB27A (Gln78Leu) previously
described (32), the Val143Ala mutation did not confer a dominant-
negative function on RAB27A in melanosome transport. These
results suggested that while the RAB27A (Val143Ala) mutant
partially impaired localization, it did not produce a dominant-
negative phenotype when over-expressed in melanocytes.
Partial melanosomal localization of EGFP-RAB27A (Val143Ala)
in melan-a cells further prompted us to investigate whether this
mutant supports melanosome transport in the absence of anFrontiers in Immunology | www.frontiersin.org 6endogenous mouse RAB27A. To this end, we stably expressed the
Val143Ala variant in RAB27A-deficient immortalized melanocytes
[melan-ash cells (26);] that typically showed perinuclear aggregation
ofmelanosomes (Figure 4A, upper right panel).When the wild-type
EGFP-RAB27A was stably expressed in the melan-ash cells, it was
clearly localized to melanosomes (Figure 4A, middle panels), and
more than 90% of melan-ash cells expressing EGFP-RAB27A
restored the peripheral distribution of melanosomes (Figure 4B).
Ontheotherhand,unlike in thecaseofmelan-acells,EGFP-RAB27A
(Val143Ala) showed punctate localization on melanosomes in
melan-ash cells (Figure 4A, lower panels) and rescued the
perinuclear aggregation phenotype, although less efficiently than
EGFP-RAB27A (Figure 4B). Such partial rescue effect of EGFP-
RAB27A (Val143Ala) is likely to be attributable to its lower
expression level in melan-ash cells (Figure 4C) because there is a
clear positive correlation between the protein expression level of
RAB27A (Val143Ala) and rescue efficiency (data not shown).A
B D E
C
FIGURE 2 | Impaired degranulation and killing of patient cytotoxic T cells (A). Ex vivo degranulation of cultured cytotoxic T cells from the patient, heterozygous
mother, and a healthy control after incubation with medium (dotted line) or with 1 µg/ml anti-CD3 + L1210 cells was measured by surface expression of CD107a
using flow cytometry (B). Collected mean intensity fluorescence (MFI) of 3 independent experiments showing the difference (delta MFI) between unstimulated and
stimulated cells (C). Lytic granule mobilization to an artificial immunological synapse was normal of patient and mother CTLs. Microscope slides were coated with
10 µg/ml anti-CD3, CTLs were settled for 10 min, PFA fixed, permeabilized with saponin, and stained for actin (white), pericentrin (yellow), and lytic granules (red).
Shown are single slices from the artificial synapse interface formed on the microscope slide and a 90°C rotation of all sliced showing the location of the lytic granules
close to the pericentrin. Bottom of the microscope slide in the 90°C side view (plate-bound CD3 localization), is indicated by a red line (D). Percentage lysis of P815-
NucLight Red targets over time measured by IncuCyte killing assay using two healthy controls (CTR), the mother and patient CTLs overtime measured for 4 h
(E). Protein analysis by western blotting showed normal protein expression of RAB27A in the mother and the patient’s CTLs. To show specificity of the RAB27A
antibody a human RAB27A knockout (RAB27-/-) CD8+ cell line was run in parallel.December 2020 | Volume 11 | Article 612977
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melanosomes did not accumulate in the peripheral area of RAB27A
(Val143Ala)-expressingmelan-ash cells when compared to the wild-
type RAB27A-expressing cells (Figure 4A).
Effect of the Val143Ala Mutation of
RAB27A on Binding Activity Toward SLP2-
A, MLPH/SlLAC2-A, and MUNC13-4
Because RAB27A is known to regulate actin-based melanosome
transport inmelanocytes and lytic granule exocytosis in cytotoxic T
lymphocytes through interaction with cell-type-specific or tissue-
specific effectors (33), we finally investigated the effect of the
Val143Ala mutation of RAB27A on binding activity toward its
effectors. We selected three well-known RAB27A effectors, i.e.,
mouse SLP2-A, MLPH/SLAC2-A, and MUNC13-4, that function
in melanocytes and/or cytotoxic T lymphocytes (6, 7, 34–38) andFrontiers in Immunology | www.frontiersin.org 7performed co-immunoprecipitation assays in COS-7 cells by co-
expressing FLAG-tagged RAB27A and T7-tagged RAB27A
effectors. The results showed that the Val143Ala mutation
dramatically reduced the binding activity toward MUNC13-4 and
SLP2-A (Figures 5A, B). Intriguingly, however, it had no effect on
the binding activity toward MLPH/SLAC2-A (Figure 5C).
Consistent with the normal MLPH/SLAC2-A binding activity of
RAB27A (Val143Ala), its expression in melan-ash cells mostly
rescued the perinuclear aggregation phenotype, i.e., the typical
MLPH/SLAC2-A-deficient phenotype (Figures 4A, B). However,
because RAB27A(Val143Ala) showed decreased SLP2-A binding
activity (Figure 5B), melanosomes did not accumulate in the
peripheral area in RAB27A (Val143Ala)-expressing melan-ash
cells (Figure 4A, bottom right panel, boxed), which is a typical
peripheral dilution phenotype observed in SLP2-A-deficient
melanocytes (38). Taken together, these results indicated that the
Val143AlamutationofRAB27Adifferently affectedbindingactivity
toward RAB27A effectors.DISCUSSION
In the present study, we biochemically and functionally analyzed
a novel homozygous RAB27A mutation (Val143Ala) found in a
GS-2 patient without albinism. Defective CTL degranulation and
cytotoxic functions confirm the functional relevance of the
mutation for lymphocyte cytotoxicity, explaining the HLH
predisposition phenotype of the patient.
The effect of the Val143Alamutation inmelanocyteswas clearly
different from that of two previously characterized GS-2mutations
(Lys22Arg and Ile44Thr) with partial albinism in our previous
studies. The Lys22Arg mutation caused cytosolic localization of
EGFP-RAB27A (Lys22Arg) because of its defect in GTP binding
activity, whereas the Ile44Thr mutation had no effect on the
melanosomal localization of RAB27A (Ile44Thr) (25). The
Val143Ala mutation of RAB27A may also affect the folding of
RAB27A, which consequently destabilizes the mutant protein
leading to its degradation or its inefficient melanosome targeting,
at least inmelanocytes. However, since the decreased expression of
RAB27A protein was not observed in the patient’s CTLs, certain
chaperones that express only in CTLs might stabilize mutant
RAB27A protein. In contrast to the Val143Ala mutation, either
the Lys22Arg or Ileu44Thr mutation completely impaired MLPH/
SLAC2-A-binding activity (25), which is presumably the primary
cause of partial albinism of these GS-2 patients.
We noted the fact that Val143 of human RAB27A is located at a
bend region between the b5 strand and the a4 helix of the common
RAB GTPase structure and that it is not located in the consensus
phosphate/magnesium-binding motifs or guanine base-binding
motifs. However, Val in this position is invariant among the
RAB27 subfamily proteins from different species (25) and highly
conserved among the mammalian RAB family proteins. Moreover,
Val143 of RAB27A/B does not directly interact with either MLPH/
SLAC2-A or SLP2-A based on the crystal structure of the MLPH/
SLAC2-A-SHD–RAB27B complex (39) and SLP2-A-SHD–
RAB27A complex (40). We thus suggest that the Val143Ala
mutation may indirectly affect the spatial position of criticalFIGURE 3 | Subcellular localization of RAB27A(Val143Ala) mutant and its
effect on melanosome distribution in wild-type melanocytes. Melan-a cells
stably expressing either EGFP alone (top panels), EGFP-RAB27A (WT, wild-
type) (middle panels), or EGFP-RAB27 (Val143Ala) (indicated as V143A;
bottom panels) (EGFP in green and DAPI in blue). The insets show magnified
views of the boxed areas (melanosomes are pseudo-colored in magenta).
Note that RAB27A (Val143Ala) was mostly present in the cytosol and only
weakly co-localized with melanosomes, whereas wild-type RAB27A was
present on melanosomes. Scale bars, 20 µm.December 2020 | Volume 11 | Article 612977
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SLP2-A binding. Further detailed structural analysis is necessary to
determine the Val143Ala mutation’s impact on the RAB27A–SLP2-
A interaction.
To date, a total of 16 patients from twelve families have been
reported topresentwithGS-2 sinealbinism(12–15).The studyof these
RAB27A variants suggests potential mechanisms underlying this
atypical GS-2. First, mutations at residues Arg80, Arg82, Arg141,
and Val143 that lie on the surface of the protein may directly
interact with MUNC13-4 while these and other internal residuesFrontiers in Immunology | www.frontiersin.org 8may lead to conformational changes in RAB27A that disrupt this
binding (12, 13) (Figure 6). Othermutations, such as Arg184, seem to
disrupt protein stability, leading to a loss of RAB27A in patient cells
(14). Additionally, the study of a 5’ untranslated region structural
variant linked the lack of hypopigmentation to differential RAB27A
transcription start sites usage between lymphocytes and melanocytes
(14). The study of compound heterozygous RAB27A variants showed
that the presence of one such allele is sufficient to preserve normal
pigmentation (12, 14). Clinically, the age of onset and clinical
presentation of HLH seem to be similar to typical GS-2. GS-2 sineA B
C
FIGURE 4 | RAB27A (Val143Ala) partially restored peripheral melanosome distribution in RAB27A-deficient melanocytes (A). Melan-ash cells stably expressing either EGFP
alone (top panels), EGFP-RAB27A (WT, wild-type) (middle panels), or EGFP-RAB27A (Val143Ala) (indicated as V143A; bottom panels) by retrovirus infection (EGFP in green
and DAPI in blue). The insets show magnified views of the boxed areas (melanosomes are pseudo-colored in magenta) and indicate the association of EGFP-RAB27A
(Val143Ala) with melanosomes in melan-ash cells. Note that expression of wild-type RAB27A in melan-ash cells completely rescued the perinuclear aggregation phenotype
(i.e., peripheral melanosome distribution), whereas expression of RAB27A (Val143Ala) did partially. Scale bars, 20 µm (B). Quantification of the cells with peripheral
melanosome distribution shown in (A). The results are expressed as the percentages of infected cells exhibiting peripheral melanosome distribution (means ± S.E. of three
determinations; n > 25 in each determination). ***p < 0.001 (Tukey’s test) (C). The protein expression level of EGFP-RAB27A (WT) and EGFP-RAB27A(Val143Ala) in
blasticidin-selected melan-ash cells. Cell lysates were subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed by immunoblotting
with the antibodies indicated. The positions of the molecular mass markers (in kilodaltons) are shown on the left.December 2020 | Volume 11 | Article 612977
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Frontiers in Immunology | www.frontiersin.org 9albinismpatientspresentwithahighrateofneuroinflammation(44%).
Lung involvement and skin granuloma were presented in three and
two patients, respectively. Interestingly, two patients presented with B
cell lymphoma, which is not reported in typical GS-2. The importance
of suchclinicalfindings in thecontextofpresentedmutations isunclear
at present.
In conclusion, the results of our analyses of the Val143Ala
mutation of RAB27A can explain the phenotype of the GS-2
patient without albinism. The Val143Ala mutation impairs both
the RAB27A–SLP2-A interaction and RAB27A–MUNC13-4
interaction, but it has no effect on the RAB27A–MLPH/
SLAC2-A interaction that is crucial for skin and hair
pigmentation (8, 41). Because SLP2-A knockout mice showed
neither immunodeficiency (34) nor severe hypopigmentation
(42), certain compensation for the SLP2-A-mediated docking
step would occur in CTL secretion and melanosome transfer to
keratinocytes in vivo. We thus conclude that disruption of the
RAB27A–MUNC13-4 interaction in cytotoxic lymphocytes leads
to the impaired cytotoxicity, the immunodeficiency, and the
predisposition to HLH of the GS-2 patient with homozygous
Val143Ala mutation, as has been shown in jinx mice and type 3
familial hemophagocytic lymphohistiocytosis (FHL3) patients
(31, 37, 43). RAB27A mutations should be investigated in
patients with suspected HLH disease, even if there is no
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